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Abstract: A large number of studies have focused on identifying molecular biomarkers, including
microRNAs (miRNAs) to aid in the diagnosis and prognosis of the most common subtypes of
non-Hodgkin lymphoma (NHL), Diffuse Large B-cell Lymphoma and Follicular Lymphoma. NHL is
difficult to diagnose and treat with many cases becoming resistant to chemotherapy, hence the need
to identify improved biomarkers to aid in both diagnosis and treatment modalities. This review
summarises more recent research on the dysregulated miRNA expression profiles found in NHL,
as well as the regulatory role and biomarker potential of cellular and circulating miRNAs found in
tissue and serum, respectively. In addition, the emerging field of research focusing on miRNA single
nucleotide polymorphisms (miRSNPs) in genes of the miRNA biogenesis pathway, in miRNA genes
themselves, and in their target sites may provide new insights on gene expression changes in these
genes. These miRSNPs may impact miRNA networks and have been shown to play a role in a host of
different cancer types including haematological malignancies. With respect to NHL, a number of
SNPs in miRNA-binding sites in target genes have been shown to be associated with overall survival.
Keywords: B-cell lymphoma; lymphoid neoplasia; haematological malignancies; micro-RNA
(miRNA/miR); circulating miRNA; miRSNP (micro-RNA single nucleotide polymorphism);
biomarker
1. Introduction
Non-Hodgkin lymphoma (NHL) is biologically distinct from classical Hodgkin lymphoma and
comprises a heterogeneous group of lymphoid malignancies involving uncontrolled proliferation of
B-, T- and natural killer lymphocytes. Global incidence rates of NHL have been steadily increasing
with the highest incidence occurring in developed regions, such as North America, Europe and
Australasia [1]. There are over 50 subtypes of NHL, the most common being Diffuse Large B-cell
Lymphoma (DLBCL) and Follicular B-cell Lymphoma (FL) [1]. NHL is the fifth most common cancer
worldwide, with incidence trends occurring more in older white men, over the age of 70 years; however
trends in young men are in line with the human immunodeficiency virus (HIV) epidemic [1]. Rates of
DLBCL increase dramatically by the age of 50 years and rates of FL increase from 30 to 70 years [2].
The difference in incidence between racial groups is possibly due to ethnic variations in genes that are
involved in regulating the immune system [3]. In the United States in 2012, overall incidence rates of
lymphoma were 51% higher in males than females, with occupational exposures during industrial
or farm work being the most likely reason for these gender differences, although there is no male
dominance in incidence in FL cases [2]. The over-proliferation of lymphocytes may be triggered by
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a wide range of factors, including exposure to hazardous chemicals, immunosuppressive therapy,
immunodeficiency disorders, infection with HIV and Epstein-Barr virus (EBV), heritable genetic risk
factors and chromosomal translocations [1,4,5]. DLBCL is diagnosed more frequently than any other
lymphoma in adults (up to 40% of cases) and is the most aggressive form of NHL [6]. It is complex
to diagnose and treat due to its clinical, pathological and molecular diversity and is considered to
consist of different disease entities requiring different forms of treatment [6]. Early gene expression and
immunohistochemistry profiling studies have identified three main subgroups of DLBCL: germinal
centre B-cell like DLBCL (GCB-DLBCL), activated B-cell-like DLBCL (ABC-DLBCL), and also primary
mediastinal DLBCL (PMBL) [7–9]. GCB-DLBCL cases have a much better prognosis and survival rate
than those with ABC-DLBCL [9]. DLBCL can present “de novo” or as a high-grade transformation
from an already diagnosed case of late stage FL [10]. 3-5% of B-cell chronic lymphocytic leukaemia
(B-CLL) cases can also transform into DLBCL, called Richter Syndrome [11,12]. FL cases are more
indolent than DLBCL and are the second most common of the B-cell tumours (30% of cases) [13]. In FL
up to 90% of cases are caused by the t(14;18) translocation, which leads to deregulated expression of the
anti-apoptotic B-cell lymphoma 2 (BCL2) protein [14]. As a result of the difficulties in characterisation
and management of DLBCL and FL, a number of studies have focused on identifying molecular
biomarkers, including microRNAs (miRNAs or MiRs) to aid in their diagnosis and prognosis, and
they will be reviewed here.
MiRNAs are short sequences of ribonucleic acid (RNA) that are coded for by miRNA gene
sequences of deoxyribonucleic acid (DNA). MiRNAs themselves are non-coding, but are highly
complementary to the 3′-untranslated regions (3′ UTRs) of target sequences of transcribed messenger
RNA (mRNA) and when a miRNA molecule binds to its specific target it can either inhibit protein
translation or cause degradation of the mRNA molecule [15]. In this way, miRNAs act as regulatory
molecules and play a role in the negative posttranscriptional regulation of gene expression. A single
miRNA is able to target several mRNAs with near perfect base pairing of the 5′ miRNA seed region to
its mRNA target, and a single mRNA can be targeted by various miRNAs [16]. The last decade has
produced extensive research on miRNAs in cancer with these small, non-coding molecules shown to
modulate important cellular processes such as cell growth, proliferation, differentiation, survival and
apoptosis [16]. As they are often located at fragile sites and genomic regions on chromosomes that
are associated with cancer, they are now studied in almost all cancer types and have been shown to
be able to function as either oncogenes or tumour suppressors, and so play a critical role in tumour
development [17,18].
Recent advancement in small RNA deep sequencing technology has now enabled the identification
of over 2500 mature human miRNAs, according to the latest version of the miRNA database in 2014,
miRBase v21 (http://www.mirbase.org/) [19]. The processing pathway and biogenesis of miRNAs
has been well characterised in other reviews [20,21] and will not be discussed here.
The majority of mature miRNAs are processed in the cytoplasm and function intracellularly,
however some have been found to occur in extracellular circulating environments, such as serum
and plasma [22]. Several studies have used the quantitative reverse transcription polymerase chain
reaction (qRT-PCR) method to quantitate the levels of miRNA in plasma or serum from cancer patients,
to show their use as a potential diagnostic biomarker or tool for predicting disease response [23–25].
Chakraborty et al. [26] have recently reviewed cell-free and circulating miRNAs as a diagnostic tool
for different cancer types, and they neatly summarise how extracellular miRNAs are secreted through
three different pathways, i.e., enclosed within an exosome, enclosed within an apoptotic body and
enclosed within a shedding vesicle. Tumour-specific miRNAs in the circulation may be the result
of dying or lysed tumour cells releasing exosomes containing miRNAs [27], however there is also
evidence of an active release of exosomes containing miR-222 from melanoma tumour cells [28].
Circulating miRNAs are therefore highly stable molecules as they have external protection from
RNAse activity with reproducible levels in tumours and biofluids. They provide specific expression
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patterns or “fingerprints” for different diseases and show potential as a novel type of non-invasive
tumour biomarker for cancer diagnosis and prognosis [22].
Single nucleotide polymorphisms or SNPs are single base variations in the DNA sequence. If they
result in a codon that codes for an alternate amino acid in the protein sequence they are referred to as
missense mutations and may affect protein function, however the majority fall in non-coding regions
of the genome and if they have an effect it is most likely to be on gene regulation. Increasing evidence
has shown that SNPs in the 3′ UTRs of target mRNAs may affect complementary binding of multiple
mature miRNA sequences and thus result in numerous functional consequences including aberrant
gene expression and development of tumours [20]. SNPs that affect miRNA expression could also
potentially be located in genes in the miRNA biogenesis pathway, as well as in the miRNA genes
themselves. Many researchers are now starting to investigate these SNPs and their functional role in
disease susceptibility and outcome. To date, several miRSNPs have been identified in haematological
malignancies with only a few so far identified in lymphoma [29].
2. Dysregulated miRNA Expression Profiles in NHL
B-cell NHL is comprised of a number of different subtypes, including DLBCL, FL, Mantle
Cell Lymphoma (MCL), Burkitt Lymphoma (BL), Mucosa-Associated Lymphoid Tissue (MALT),
and Marginal Zone Lymphoma (MZL). Since the discovery of miRNAs and their role in tumorigenesis,
researchers have aimed to quantitate levels of miRNAs and determine their effect on gene expression
in the different subtypes of NHL, focusing mainly on DLBCL and FL.
Evidence for the role of miRNAs in B-cell development and function came in 2007 when
Xiao et al. [30] published in Cell that miR-150 controls expression of the c-Myb transcription factor
in vivo. Metzler et al. [31] published a ground-breaking finding showing that the expression of
pre-miR-155 and its coding gene, BIC, was greatly increased in children with Burkitt Lymphoma but
not in other paediatric leukaemic samples. This data implied that other molecular factors apart from
chromosomal translocations might be involved in the development of lymphomas and opened the
door for investigation of expression of a wider selection of miRNAs in B-cell tumours. Lawrie et al. [32]
was one of the first groups to perform microarray analysis and qRT-PCR using cell lines to distinguish
between DLBCL subtypes, GCB-DLBCL and ABC-DLBCL. They first showed that miR-155, miR-21 and
miR-221 were expressed at higher levels in ABC-type than GCB-type cell lines, and that these miRNAs
were over-expressed in DLBCL and FL tumour tissues compared to healthy B lymphocytes. Subtypes
of DLBCL cases were also analysed and, consistent with expression profiles in the cell lines, these
miRNA levels were also increased in the ABC-type cells compared to GCB-type cells. Roehle et al. [6]
analysed the expression profiles of 157 known miRNAs, including those already shown to be involved
in haematopoiesis (miR-150 and miR-155) and DLBCL and FL (miR-155, miR-210, miR-106a, miR-149,
miR-139). They failed to replicate the findings of Lawrie et al. [32] as they had variable reproducibility
of immunohistochemical staining which was used to classify DLBCL subtypes, however they were able
to show differential expression profiles of 4 miRNAs to distinguish between DLBCL and FL (miR-330,
miR-17-5p, miR-106a, miR-210) with an overall accuracy of 98% (109 out of 111 cases). A 9 series
miRNA signature was later shown to differentiate ABC-DLBCL and GCB-DLBCL using miRNA
profiling and several well-characterised lymphoma cell lines where dysregulated miRNAs were
validated by qRT-PCR [33]. All nine miRNAs were expressed at a higher level in ABC- than GCB-like
cell lines (miR-17, miR-19b, miR-20a, miR-29a, miR-92a, miR-106a, miR-720, miR-1260, miR-1280).
These include 4 members of the miR-17-92 cluster (miR-17, miR-19b, miR-20a and miR-92a), which is
a set of miRNAs known to be upregulated with oncogenic potential in lymphoid malignancies [34].
Four miRNAs were shown to be differentially expressed between DLBCL and FL cell lines and normal
CD19+ controls (miR-20b, miR-26a, miR-92b and miR-487b) which were not identified in the previous
studies of Lawrie et al. [32] and Roehle et al. [6]. It should be noted that this study did not use clinical
biopsy samples, only cell lines, which further highlights the molecular heterogeneity between DLBCL
and FL immunophenotypes of cell lines and patient tissues. Fassina et al. [35] aimed to differentiate
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between clinical de novo GCB-DLBCL and non-transforming high grade (grade 3) FL cases using
a signature comprising all members of the miR-17-92 cluster (miR-18b, miR-19b, miR-20a, miR-92,
miR-93 and miR-106a) and two control miRNAs (miR-150 and miR-210). These were measured by
qRT-PCR and all were found to be significantly over-expressed in GCB-DLBCL compared to high
grade FL and allowed correct identification of 97% (35/36) GCB-DLBCL cases. A more comprehensive
investigation of miRNA expression in DLBCL and FL was performed by Lawrie et al. [10], this time
using a microarray platform containing 464 human probes, in order to validate miRNA profiles in
clinical material rather than in lymphoma cell lines. Here an unsupervised cluster analysis showed
distinct expression patterns and specific miRNA signatures, including members of the miR-17-92
cluster, for DLBCL and FL, and was able to correctly identify the subtype in >95% of cases. They were
also interested in comparing miRNA expression patterns between de novo DLBCL cases and FL cases
that had undergone transformation, and showed differential expression of 12 miRNAs that predicted
>85% of transformed versus de novo DLBCL. 6 miRNAs (miR-223, miR-217, miR-222, miR-221, let-7i
and let-7b) were dysregulated and found to predict subsequent transformation from indolent FL to
transformed DLBCL. Interestingly, the let-7 family of miRNAs had been shown previously to target
c-myc, which was associated with transformation of FL to DLBCL [36]. Although the number of FL
cases in transformation was small (n = 7), these data suggest that these miRNAs may have the potential
to identify those FL patients at risk of high-grade transformation.
More recently, global miRNA expression profiling of tumour tissue samples and cell lines
identified 27 miRNAs that enabled accurate differentiation between DLBCL and BL, including distinct
miRNA signatures for differentiation between the GCB-, ABC- and PMBL subgroups of DLBCL [37].
Their findings correspond to gene expression profile (GEP) data, however GEP methodology has not
been well accepted into clinical practice. Iqbal et al. [37] showed miR-155 to be significantly associated
with ABC-DLBCL, which was consistent with previous findings [32], while miR-28-3p and miR-28-5p
were both upregulated in GCB-DLBCL.
FL cases that lack the t(14;18) translocation and also lack BCL-2 expression run the risk of
being misdiagnosed as benign follicular hyperplasia (FH) [5]. The t(14;18)(q32.3;q21.3) translocation
involves juxtaposition of the BCL-2 oncogene on chromosome 18 to the promoter region of an
immunoglobulin heavy chain gene IgH on chromosome 14, leading to constitutive over-expression
of the anti-apoptotic BCL-2 protein [5]. Leich et al. [13] were the first group to characterise miRNA
profiles in t(14;18)-negative cases of FL. They were able to show a distinct miRNA expression profile
for 17 miRNAs in support of a late germinal centre B-cell phenotype, which could potentially give
these tumour cells a propensity for proliferation. Down-regulation of 5 miRNAs (miR-16, miR-26a,
miR-101, miR-29c and miR-138) in the t(14;18)-negative FL cases was associated with significantly
increased expression of potential target genes, such as the miR-16 target CHECK1, known to be
involved in cell cycle regulation, apoptosis and B-cell differentiation [13]. MiR-138 was also previously
identified to be differentially expressed between GCB- and ABC immunophenotypes of DLBCL de novo
cases, suggesting a partial loss of the germinal centre B-cell phenotype in t(14;18)-negative FLs [10].
As miRNAs were not yet well characterised in FL by 2012, another group analysed the miRNA profiles
of B-cell enriched FL tumour cells and FH cells from 16 patients by assaying 851 human miRNAs [38].
They showed differential expression of 133 miRNAs between FL and FH, where 44 miRNAs in three
groups generated a unique signature for FL diagnosis. A NanoString nCounter assay identified tandem
gene expression profiles for predicting miRNA targets, where functional studies identified genes
involved in cell proliferation and tumour response to chemotherapy, such as the miR-20a/-20b target
CDKN1A/p21 and the miR-194 target SOCS2 [38]. The levels of these three miRNAs were increased
while their target genes had decreased expression, indicating a potential role in lymphomagenesis
and survival. According to Akasaka et al. [39], presence of a BCL-6 rearrangement may predispose
transformation from FL to DLBCL. Two FL subtypes have been classified, e.g., FL with BCL-6 locus
rearrangement with or without BCL-2 expression (FLBCL2+/BCL6+, FLBCL2−/BCL6+) and FL with diffuse
growth (DFL) [40]. More recently Gebauer et al. aimed to identify miRNA signatures between the two
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FL subtypes. They found several miRNAs that were differentially expressed between FLBCL2+/BCL6+
and FLBCL2−/BCL6+, and also DFL, with up-regulation of oncogenic miRNAs and down-regulation of
tumour suppressor miRNAs [40]. Cluster analysis, however, showed no miRNA signatures distinct
from the reference group, that is typical FLBCL2/BCL6−, for either subtype. These data suggest an
involvement of miRNAs in the pathogenesis of FL and its subtypes, with deregulated miRNAs
corresponding to an increased risk of transformation and an inferior prognosis.
A summary of these studies on dysregulated miRNAs and their potential biomarker function in
NHL can be found in Table 1.
3. Functionally Significant Cellular miRNAs in NHL
Studies previously mentioned have focused mainly on the quantification of miRNA levels to
distinguish between DLBCL, FL and their subtypes, and have shown their potential to behave
as molecular biomarkers for diagnosis and prognosis. An aberrant miRNA signature is useful,
however it is important to be able to understand the functional role of these miRNAs and how
they regulate expression of their target genes, to enable clinicians to determine different therapeutic
modalities for individual patients as well as response to treatment and resistance to chemotherapy.
Advancement in the treatment of DLBCL includes a combination of rituximab (monoclonal antibody)
with cyclophosphamide, vincristine, doxorubicin and prednisolone (R-CHOP), which has resulted in a
large increase in overall survival rates, however up to 33% of patients will still eventually succumb to
this disease [41,42]. Studies investigating functional diagnostic as well as prognostic biomarkers in
clinical tumour tissue samples are therefore required.
Two studies have used targetome profiling to implicate specific miRNAs in lymphomagenesis [43,44].
A ribonucleoprotein immunoprecipitation-microarray (RIP-Chip)-based approach was used in HeLa
cell lines to identify members of the miR-202 and miR-618 targetome, that is, their range of target
genes. MiR-618 dysregulation has been associated with liver cancer [45] and male breast cancer [46].
MiR-202 dysregulation has been associated with breast cancer [47] and was decreased in FL cells
compared to FH cells [38] implicating a potential tumour suppressor role in lymphoma. 128 miR-618
and 141 miR-202 potential targets were identified which suggested involvement in pathways related to
haematologic function and lymphoma, however targets should still be verified in lymphoma samples.
Wang et al. [48] first screened miRNA expression profiles in DLBCL tissues and cell lines and then
performed target gene expression analysis to identify miRNAs that could be associated with lymphoma
proliferation and invasion. MiR-144 was significantly decreased in samples and cell lines and was
negatively correlated with BCL-6 expression. They showed for the first time that miR-144 directly
targets the BCL-6 gene. MiR-144 has been identified as a tumour suppressor in osteosarcoma [49]
and hepatocellular carcinoma [50]. The BCL family of proteins can have an anti-apoptotic function in
haematological malignancies and hence miR-144 appears to be a viable biomarker and therapeutic
target for lymphomagenesis [48]. It would be of interest to identify variants in the miR-144 and other
BCL-6-associated miRNAs′ precursor sequences, as well as variants in the BCL-6 target gene to perform
genetic association analysis in DLBCL and also FL cases.
MiR-21 was identified as an independent prognostic marker in de novo cases of DLBCL as high
miR-21 expression was associated with a longer relapse-free survival using Kaplan-Meier survival
analysis (p < 0.05) [32] and miR-21 inhibition in HeLa cells caused increased proliferation [51]. This data
does not seem to be in line with a functional analysis of miR-21 target genes which showed that miR-21
directly targets PTEN, which when down-regulated will allow activation of protein kinase B resulting
in significant anti-apoptotic effects in tumour cells [52]. More recently, miR-21 levels were shown to be
overexpressed in PBMCs from B-NHL patients and significantly higher in patients in stages III/IV than
I/II [53]. PTEN expression was significantly lower in patients, compared to healthy controls, which
would be expected to have an anti-apoptotic effect and shorten overall survival periods. MiR-21 levels
dropped to normal in patients in complete remission and therefore improved outcome was indicated
by a negative association of miR-21 expression and post-chemotherapy survival rates of these patients.
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Table 1. A summary and comparison of dysregulated miRNAs that could be used as potential diagnostic, subtype and prognostic biomarkers in non-Hodgkin
lymphoma (NHL).
miRNA (New Annotation [54]) Source Expression B-NHL Subtype Biomarker Reference
miR-155 (hsa-mir-155-5p),
miR-21 (hsa-mir-21-5p),
miR-221 (hsa-mir-221-3p)
Cell lines Increased ABC-DLBCL vs. GCB-DLBCL Subtype Lawrie, 2007 [32]
Patient cells and biopsy Increased DLBCL, FL vs. healthy B cells Diagnostic Lawrie, 2007 [32]
Patient cells and biopsy Increased ABC-DLBCL vs. GCB-DLBCL Subtype Lawrie, 2007 [32]
miR-155 (hsa-mir-155-5p),
miR-21 (hsa-mir-21-5p), miR-210 (hsa-mir-210-3p) Serum Increased DLBCL vs. healthy controls Diagnostic Lawrie, 2008 [23]
miR-21 (hsa-mir-21-5p)
Patient cells Increased de novo DLBCL Prognostic—longer RFS Lawrie, 2007 [32]
Serum Increased de novo DLBCL Prognostic—relapse-free survival Lawrie, 2008 [23]
Cell lines Increased ABC-DLBCL vs. GCB-DLBCL Subtype Chen, 2014 [55]
Serum Increased DLBCL vs. normal controls Diagnostic Chen, 2014 [55]
Serum Increased ABC- vs. GCB-DLBCL
Subtype Chen, 2014 [55]
Prognostic—higher in stages
II/III—improved outcome Chen, 2014 [55]
PBMCs Increased B-NHL Prognostic—higher in stages III/IV Sun, 2015 [53]
miR-330 (hsa-mir-330-3p), miR-17-5p,
miR-106a (hsa-mir-106a-5p), miR-210 (hsa-mir-210-3p) Patient biopsy Dysregulated DLBCL vs. FL Subtype Roehle, 2008 [6]
miR-125b (hsa-mir-125b-5p),
miR-143 (hsa-mir-143-3p), miR-451 (hsa-mir-451a),
miR-145 (hsa-mir-145-5p)
Patient cells and biopsy Increased DLBCL vs. FL Subtype Lawrie, 2009 [10]
miR-223 (hsa-mir-223-3p), miR-217 (hsa-mir-217),
miR-222 (hsa-mir-222-3p), miR-221 (hsa-mir-221-3p),
let-7i (hsa-let-7i-5p) and let-7b (hsa-let-7b-5p)
Patient cells and biopsy Dysregulated de novo DLBCL vs. transformed FL Subtype Lawrie, 2009 [10]
miR-17-92 cluster, miR-29a (hsa-mir-29a-3p),
miR-106a (hsa-mir-106a-5p), miR-720 (not annotated),
miR-1260 (hsa-mir-1260a), miR-1280 (not annotated)
Cell lines Increased ABC-DLBCL vs. GCB-DLBCL Subtype Culpin, 2010 [33]
miR-20b (hsa-mir-20b-5p), miR-26a (hsa-mir-26a-5p),
miR-92b (hsa-mir-92b-3p),
miR-487b (hsa-mir-487b-3p)
Cell lines Increased DLBCL vs. FL Subtype Culpin, 2010 [33]
miR-17-92 cluster, miR-150 (hsa-mir-150-5p),
miR-210 (hsa-mir-210-3p) Patient biopsy Increased GCB-DLBCL vs. high grade FL Subtype Fassina, 2012 [35]
miR-15a (hsa-mir-15a-5p), miR-16-1 (hsa-mir-16-1-3p),
miR-29c (hsa-mir-29c-3p), miR-155 (hsa-mir-155-5p) Serum Increased DLBCL vs. healthy controls Diagnostic Fang, 2012 [24]
miR-34a (hsa-mir-34a-5p) Serum Decreased DLBCL vs. healthy controls Diagnostic Fang, 2012 [24]
miR-451 (hsa-mir-451a) Bone marrow smear Decreased FL vs. normal controls Diagnostic Takei, 2014 [56]
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Table 1. Cont.
miRNA (New Annotation [54]) Source Expression B-NHL Subtype Biomarker Reference
miR-338-5p (hsa-mir-338-5p) Bone marrow smear Increased FL vs. normal controls Diagnostic Takei, 2014 [56]
miR-17-92 cluster and their paralogues
miR-18b (hsa-mir-18b-5p), miR-20b (hsa-mir-20b-5p),
miR-106a (hsa-mir-106a-5p)
Patient biopsy Increased BL vs. normal B cells and T-cells Diagnostic Iqbal, 2015 [37]
miR-155 (hsa-mir-155-5p)
Patient biopsy Decreased BL vs. DLBCL Subtype Iqbal, 2015 [37]
Activated B cells and
ABC-DLBCL cell lines Increased ABC-DLBCL vs. GCB-DLBCL Subtype Iqbal, 2015 [37]
Biopsy from patients
treated with R-CHOP Increased ABC-DLBCL Prognostic—treatment failure Iqbal, 2015 [37]
miR-155 (hsa-mir-155-5p), miR-200c (hsa-mir-200c-3p),
miR-130a (hsa-mir-130a-3p),
miR-125b (hsa-mir-125b-5p), miR-21 (hsa-mir-21-5p)
Serum Increased DLBCL vs. healthy controls Diagnostic Yuan, 2016 [57]
miR-451 (hsa-mir-451a), miR-145 (hsa-mir-145-5p) Serum Decreased DLBCL vs. healthy controls Diagnostic Yuan, 2016 [57]
miR-125b (hsa-mir-125b-5p), miR-130a Serum Increased DLBCL Prognostic—poor outcome Yuan, 2016 [57]
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Other miRNAs known to play a role in cellular proliferation and apoptosis, such as miR-224 and
miR-34a, have been analysed for prognosis and clinical outcome. 258 DLBCL patients undergoing
R-CHOP therapy were investigated for levels of miR-224 expression, which was shown to be
deregulated in other cancers [58]. MiR-224 expression was significantly lower in the DLBCL biopsy
samples (n = 258) than in normal lymphoid tissues (n = 40) with no significant difference in expression
between GCB-DLBCL and ABC-DLBCL subgroups. The authors also showed that patients with a
higher miR-224 expression level achieved an improved rate of complete remission compared with
the group expressing lower miR-224 levels [59]. MiR-34a expression was significantly lower in MALT
and DLBCL lymphoma tissues when compared to healthy lymphocytes and inversely correlated with
high expression of its target genes FOXP1, p53 and BCL-2 in stage III and IV. This was associated with
an unfavourable outcome in both lymphoma subtypes but a significantly lower overall survival in
DLBCL [60]. These changes in expression are therefore potential prognostic biomarkers for use in
clinical practice. It has been shown most recently using in vitro and in vivo studies that increased
levels of miR-34a were observed in cell lines sensitive to doxorubicin, a drug in the R-CHOP regime,
and this high expression had a prognostic impact on improved overall survival [61]. Downregulation
of FOXP1, a known target of miR-34a, could therefore potentially sensitise tumour cells to doxorubicin
and improve efficacy of the drug in chemo-resistant patients.
Iqbal et al. [37] investigated miRNA association with resistance to R-CHOP therapy and showed
miR-155 to be significantly correlated with therapy failure. As they had previously shown increased
miR-155 levels in ABC-DLBCL and downregulation of genes regulating growth factor signalling and
cell cycle, they determined therapy failure may possibly be the result of activation of the PI3K-AKT
signalling pathway [62]. Interestingly, high levels of miR-155 have been found in breast cancer cases
experiencing chemo-resistance [63]. This highlights the AKT pathway as a potential therapeutic target
for overcoming drug resistance in ABC-DLBCL patients.
4. Circulating miRNAs in NHL
MiRNAs are detectable outside of cells in blood serum and/or plasma (circulating miRNAs) and
have the potential to function as non-invasive diagnostic and prognostic markers in cancer [26,64].
Methods used for profiling circulating miRNAs are the same as those for cellular miRNAs, that is,
qRT-PCR, microarray and next-generation or deep sequencing [26]. Only a few studies have attempted
to investigate circulating miRNA profiles in patients with NHL with promising results for diagnosis,
subtype classification, prognosis and response to R-CHOP treatment. Lawrie et al. [23] were the first to
publish their discovery of circulating miRNAs in biological fluids in any disease. They used qRT-PCR
to detect miRNAs in the serum of DLBCL patients and showed differential expression of these miRNAs
in patients and healthy controls. Similar to their previous study investigating differential expression
of miRNAs in tumour cells [32], they were able to show increased expression of tumour-associated
miRNAs (miR-155, miR-210 and miR-21) in the serum of DLBCL patients compared to control sera
samples [23]. They showed that increased serum miR-21 expression was significantly associated with
relapse-free survival in these patients, which is in keeping with their findings on the prognostic value
of miR-21 in de novo DLBCL cases [32], however they did not directly correlate miR-21 levels in
tumour cells and serum in the same cohort of patients. A follow up study by Chen et al. [55] confirmed
these findings in a Chinese population and showed that not only was miR-21 expression higher in
ABC-DLBCL serum compared to GCB-DLBCL serum, but the circulating levels of miR-21 in sera
from DLBCL patients was significantly associated with matched tumour tissue samples (p = 0.0001).
Furthermore, miR-21 upregulation was higher in stages I/II compared to III/IV, which contradicts later
findings in PBMCs by Sun et al. [53] mentioned earlier, and significantly associated with improved
prognosis. This discrepancy could be due to alternative miR-21 sources being used in different studies,
or it could mean there are other miR-21 targets influencing apoptosis or cellular proliferation that have
not yet been discovered. Altogether these findings highlight the potential of serum miR-21 to function
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as a diagnostic and prognostic non-invasive biomarker for DLBCL and its subtypes, however studies
should be validated in other larger populations.
Another group measured levels of 7 miRNAs in serum of DLBCL patients compared to healthy
controls using qRT-PCR and showed 4 miRNAs to be significantly increased in DLBCL (miR-15a,
miR-16-1, miR-29c, miR-155) while miR-34a was decreased [24]. These data could serve as the basis for
further functional studies in larger populations as there are limitations to this study, such as the small
sample size (n = 75) and measuring low levels of miRNAs with the lack of standard curve calibration
in their qRT-PCR assay.
More recently Yuan et al. [57] aimed to investigate the correlation, if any, between circulating
miRNAs and chemoresistance in DLBCL patients. At first they showed dysregulated expression of
eight miRNAs in serum from 56 DLBCL patients prior to treatment compared to healthy controls:
miR-155, miR-200c, miR-130a, miR-125b and miR-21 were upregulated, whereas miR-29c, miR-451
and miR-145 were downregulated. They also showed a significant association of these miRNAs
between serum and matching tumour biopsy samples. Out of the 56 patients, 21 experienced
resistance to R-CHOP, and 35 were sensitive to the therapy. The group found that only miR-130a and
miR-125b expression was significantly upregulated in the drug resistant group compared to the drug
sensitive group and in addition, high levels of miR-130a and miR-125b were associated with a worse
prognosis using Kaplan-Meier survival analysis curves, however this was only significant for miR-125b,
as miR-130a was not significant after Multivariate Cox regression analysis [57]. Another study showed
a correlation between miR-21 knock-down in a DLBCL cell line and decreased resistance to CHOP
treatment [65], however Yuan et al. [57] were not able to show that increased serum miR-21 levels
increased resistance to R-CHOP in their study.
Serum miRNA levels are evidently promising non-invasive biomarkers of DLBCL, however
further studies are required for validation and elucidation of molecular mechanisms of serum miRNAs
in drug resistance and prognosis. No studies to date have investigated serum miRNA levels in FL
or other less common NHL subtypes. As bone marrow involvement can occur in 50% of grade 1
FL cases [66], one study has measured miRNA levels in bone marrow smears from FL patients, and
identified an aberrantly expressed miRNA profile between FL patients and normal controls using a
TaqMan real time PCR miRNA array method [56]. 39 miRNAs were significantly decreased, of which
miR-451 was the most decreased, and 27 miRNAs were significantly increased, of which miR-338-5p
showed the highest increase. The authors claim these miRNAs may serve as biomarkers to predict the
invasion of FL cells into the bone marrow without having to perform a biopsy, and that bone marrow
smear samples could serve as another reliable source of miRNAs. A summary of these studies on
circulating miRNAs can also be found in Table 1.
5. MiRNA-Related SNPs in NHL
Genetic variation in microRNA regulatory pathways in cancer are now being investigated in
depth. These polymorphisms can occur in miRNA biogenesis pathway genes, in miRNA genes in
different regions, i.e., pre-miRNA, seed or mature sequences, and in miRNA-binding site target genes.
These polymorphisms may alter miRNA function as either an oncogene or tumour suppressor and
potentially behave as diagnostic and prognostic biomarkers for clinical use. These miRNA variants
or SNPs (miRSNPs) have been extensively reviewed in a range of cancer types [20,67,68], including
haematological malignancies [29], however no reviews to date have summarised the new research on
these miRSNPs in NHL specifically. Currently the significant miRSNPs identified in NHL are very
few with even fewer functional studies to back them up and have only been observed in particular
subtypes, although in some studies there has been no stratification of subtypes and all patients are
classified as NHL.
The first report of an association between a heritable polymorphism at a miRNA locus and
lymphoma was in 2012 when Schuetz et al. [69] found a variant near miR-155 (rs928883) using Sanger
sequencing, and found it to be significantly associated with risk of MZL in Caucasians of European
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ancestry after correction for multiple testing (p = 0.0272). Functional analysis was not carried out for
this SNP. Four mutations in the mature miR-142-5p/-3p sequences, and three in the miR-142 precursor
sequence, were identified by Kwanhian et al. [70] in the same year, who also claimed to have made the
first report describing mutations in a miRNA gene in a lymphoma subtype, DLBCL. Their functional
analysis showed a potential loss of function for these mutations and loss of responsiveness of the
known miR-142-3p targets RAC1 and ADCY9.
Two polymorphisms were identified in the ethnic Han Chinese, that is, miR-146a rs2910164 and
miR-196-a2 rs11614913, which were both significantly associated with an increased risk of DLBCL and
NHL, respectively [71,72]. The rs11614913 T > C variant is located in the miR-196-a2 gene and was
shown by Hoffman et al. [17] to possibly play an oncogenic role in breast cancer by leading to less
efficient processing of the miRNA precursor and reduced capacity of the mature form to influence its
targets. Li et al. [72] performed a genotype-phenotype correlation analysis on NHL tissue samples
(n = 59) and confirmed that the rs11614913 TC/CC genotype affects levels of mature miR-196-a2
expression with an increase in expression in carriers of the variant C allele. Furthermore, miR-196-a2
rs11614913 was inversely associated with NHL susceptibility in Caucasian participants only in an
AIDS-NHL cohort [73]. The rs2910164 G > C variant is located in the stem structure of the miR-146a
precursor sequence. Zhuang et al. [71] showed that miR-146a expression was significantly upregulated
in DLBCL patients (n = 56) compared to controls (n = 28) and the polymorphism affects levels of
mature miR-146a expression with a significant decrease in expression in patients with the CC genotype.
Interestingly, we had shown a genetic association between miR-146a rs2910164 (G > C) and increased
susceptibility to sporadic breast cancer in an Australian case-control cohort [74]. Validation of these
findings is required in other larger DLBCL populations of different ethnicities and further functional
analyses should be carried out.
MiR-618 and miR-202 were found to play a direct role in follicular lymphomagenesis with variants
in their precursor sequences showing a significant association with FL by influencing levels of target
gene expression. The pre-miR-618 SNP rs2682818 and pre-miR-202 SNP rs12355840 were genotyped
in a population-based case-control study of 455 NHL patients and 527 controls where individuals
with one or both of the variant alleles were at a higher risk for FL [43,44]. Vectors were used to test
the functional effect of the variant and wild type alleles on miR-618 and miR-202 expression and
were transfected into HeLa cells, after which levels of primary and mature miRNA transcripts were
measured by qPCR. They were able to show that presence of the variant T and G alleles can reduce
in vitro production of mature miR-618 and miR-202 levels, respectively. Due to a lack of patient RNA
samples, however, they were not able to directly correlate their genotyping data with miRNA gene
expression [43,44]. These studies are some of the first to investigate the functional tumour suppressor
role of miRSNPs in lymphomagenesis, however expression levels of miR-618 and miR-202 and their
identified targets require examination in clinical samples.
One study looked at SNPs located in the miRNA processing genes to determine an association
with NHL. An independent association was found after multivariate analysis between rs197412 located
in the coding region of GEMIN3 (together with RISC, GEMIN3 will aid in selection of one strand of the
miRNA duplex as the mature miRNA and guide it to its target) and overall survival in NHL patients
(p = 0.013) which also carried over to the DLBCL and T-cell lymphoma subtypes in their cohort [75].
Furthermore, this SNP has also been associated with AIDS-NHL susceptibility with evidence to show
that variation in this gene may affect miR-222 expression [73].
Polymorphisms located in the 3′ UTRs of miRNA target genes may affect the precision
complementarity and binding affinity between miRNA binding sites and their target mRNAs and
therefore disrupt gene expression and protein levels [29]. These SNPs occur more frequently in the
genome affecting only target gene expression and its downstream pathway effectors leading to a
limited range of effects [68]. A few studies have identified SNPs in 3’ UTR targets that disrupt miRNA
binding sites and have been shown to have an effect on gene expression and clinical significance in
cancer patients [76–78]. A number of these SNPs have also been identified in individual studies in
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NHL and associated with disease prognosis. Li et al. [79] identified multiple variants by sequencing
the 3′ UTR of the TP53 gene in DLBCL patients and confirmed that they have prognostic significance.
Three novel single nucleotide variants were shown to disrupt miR-125b binding to their TP53 target
causing upregulation of p53 expression and an increase in apoptosis, while in contrast the rs78378222
CC SNP located in the polyadenylation signal (PAS) and not a putative miRNA binding site, was
shown to reduce p53 expression and subsequently reduced apoptosis. Three studies on Han Chinese
NHL patients were performed by collaborating authors on known SNPs in 3′ UTRs of miRNA targets
in order to investigate an association between these SNPs and disease outcome [80–82]. The first study
investigated four SNPs and showed the rs3660 SNP GG genotype in the KRT81-miR-17 interaction
was significantly associated with poorer outcome (p = 0.003) after multivariate analysis [80]. Similarly,
this SNP was previously associated with tumour recurrence and worse overall survival in multiple
myeloma [83]. The second study evaluated the effect of a polymorphism in the SET8 3′ UTR and
showed the rs16917496 CC genotype of the SNP in the miR-502 binding site was significantly associated
with increased survival (p = 0.041) after multivariate analysis [82] and may have prognostic value in
a clinical setting. Thirdly, an analysis was performed on another four SNPs, however the disrupted
miRNA binding sites were not specified. The rs4901706 AA genotype of the C14orf101 3′ UTR was
significantly associated with a longer overall survival (p = 0.015) and was identified as an independent
predictor of overall survival (p = 0.033) by multivariate analysis [81]. None of these studies, however,
showed any significant associations between these and other miRNA binding site SNPs and risk of
NHL in their case-control cohorts. Peckham et al. [73] found an increased risk for systemic HIV/AIDS
NHL compared to HIV positive controls with the variant allele of the HIF1A 3′ UTR SNP rs2057482
located within a miRNA-196a binding site.
The results from these studies are preliminary and the underlying mechanisms behind how these
SNPs influence risk and survival in NHL remain unclear. Therefore validation in other populations
and functional in vitro experiments in clinical tumour samples should be performed to confirm and
elucidate these findings. A summary of these studies can be found in Tables 2 and 3.
6. Challenges and Future Developments
DLBCL is an aggressive cancer with up to 40% of patients unable to achieve relapse-free survival
with primary therapies. Studies that set out to investigate methods that enable early diagnosis and
subtype classification as well as prediction of drug resistance and disease outcome for individual
patients are of paramount importance. Over the last decade researchers have identified distinct
miRNA profiles for the diagnosis and prognosis of the common subtypes of NHL, and some have
gone on to further investigate the regulatory roles these miRNAs play in lymphomagenesis, enabling
improvements in clinical management.
Methodologies used to measure miRNA levels in tumour biopsies and biofluids include
qRT-PCR, microarray and next generation sequencing (NGS), while deep sequencing of small miRNAs
(miRNA-seq) has been recently developed to allow the discovery of novel biomarker miRNAs and
can be performed on different high-throughput platforms, including Ion Torrent and Illumina. While
NGS is more rapid and advanced, there is still a level of bias between microarray and deep sequencing
identification and quantification of miRNAs in terms of base composition [84]. As a result, biomarkers
discovered through NGS should be carefully considered and properly validated. Using sequencing
miRNA profiles for determination of subtype and survival adds prognostic value to the Revised
International Prognostic Index (R-IPI) which is equivalent to the gold standard for selecting patients
with a poor outcome [85]. MiRNA-seq was used in a recent study to profile DLBCL patient samples
and perform an integrated analysis of the DLBCL miRNA targetome (miRNome) [86]. Lim et al. [86]
used two cohorts, discovery and validation, in which five known and one unknown novel candidate
miRNA (miR-28-5p, miR-324-5p, miR-214-5p, miR-339-3p, miR-5586-5p, NOVELM00203M) were
associated with patient survival, independently of the IPI scores. The miRNA-seq data was integrated
with gene expression data from the same patients which revealed that upregulation of miRNAs in
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DLBCL can lead to aberrant regulation of genes involved in epigenome modulation, and comparison
of patient profiles with miRNA-seq libraries of other diseases identified miRNAs (including three
novel candidates) that were specifically involved with B-cell biology, suggesting these miRNAs may
be involved in lymphomagenesis [86].
Cammaerts et al. [87] have developed a software tool for predicting the impact of gene variants
on miRNA expression, called miRVas. This was designed to overcome time-consuming processes
and manual errors experienced with determining secondary miRNA structures with variants using
the miRSNP database tool, especially when more than one variant is investigated. Also, for novel
variants, databases cannot be used to obtain variant information. Hence, the miRVas tool is more
user-friendly and can speed up and facilitate evaluation of the impact of several genetic variants
on miRNAs simultaneously. As functional analysis of miRSNPs is costly and takes time, and with
the availability of increasing sequencing driven identification of variants in or near miRNA genes,
it is necessary to accurately predict a functional effect to enable selection of the most appropriate
candidates for further analysis.
The biggest challenge with qRT-PCR or microarray miRNA profiling of biofluids is the lack of a
suitable normalisation control or internal reference miRNA. Endogenous controls (ECs) such as small
nucleolar RNAs (snoRNAs) have been validated for use in serum and plasma samples [88]. It was
found that U6 is unsuitable as an EC, while miR-16 and miR-24 have stable levels of expression and are
less likely to degrade after repeat freeze-thaw cycles. According to Mestdagh et al. [89], it is possible
that mean miRNA expression levels can reduce variation between samples and more accurately detect
aberrant expression profiles rather than using ECs. Although NGS is more specific and able to detect
novel mature miRNA isoforms (isomiRs), it may not detect lower levels of miRNAs in biofluids,
and so qRT-PCR or Nanostring nCounter assays are perhaps more feasible for serum and plasma
profiling [90].
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Table 2. A summary of single nucleotide polymorphisms in miRNA genes or their processing genes and their association and function in different non-Hodgkin
lymphoma (NHL) populations and subtypes.
miRNA Gene/
Processing Gene New Annotation [54] SNP/Mutation B-NHL Subtype Association/Function Population Reference
hsa-miR-155 hsa-miR-155-5p rs928883 (A > G) MZL Increased risk Canadian (569 cases vs. 547 controls) Schuetz, 2012 [69]
miR-142, miR-142-5p,
miR-142-3p
hsa-miR-142-5p
hsa-mir-142-3p DLBCL
20% of cases are mutated
with a loss of function European (56 cases) Kwanhian, 2012 [70]
Pre-miR-202 hsa-mir-202 rs12355840 (A > G) FL Increased risk American (455 cases vs. 527 controls) Hoffman, 2013 [43]
Pre-miR-618 hsa-mir-618 rs2682818 (G > T) FL Increased risk American (455 cases vs. 527 controls) Fu, 2014 [44]
Pre-miR-146a hsa-mir-146a rs2910164 (G > C) DLBCL Increased risk Chinese (280 cases vs. 300 controls) Zhuang, 2014 [71]
miR-196a2 hsa-mir-196a2 rs11614913 (T > C)
NHL Increased risk Chinese (318 cases vs. 320 controls) Li, 2015 [72]
CNS HIV/AIDS NHL Decreased risk American HIV+ men(180 cases vs. 529 controls) Peckham, 2014 [73]
GEMIN3 rs197412 (T > C)
NHL/DLBCL Independently associatedwith overall survival Chinese (168 cases vs. controls) Gao, 2015 [75]
HIV/AIDS NHL Increased risk withincreased serum miR-222
American HIV+ men
(180 cases vs. 529 controls) Peckham, 2014 [73]
Table 3. A summary of single nucleotide polymorphisms and novel single nucleotide variants in the 3’UTRs of miRNA target genes and their association and function
in different non-Hodgkin lymphoma (NHL) populations and subtypes, PAS, polyadenylation signal; SNV, single nucleotide variant.
Target Gene Disrupted miRNA BindingSite (New Annotation [54]) SNP B-NHL Subtype Association/Function Population Reference
TP53 3′ UTR
Germline SNP in PAS sequence rs78378222 (A > C)
DLBCL
Decreased p53 protein expression and
reduced apoptosis with CC genotype/
prognostic significance
American (244 cases training
set and 247 cases validation set) Li, 2013 [79]
miR-125b (hsa-miR-125b-5p) 3 novel SNVs(733U, 737A, 739A)
Negative regulation pf p53 altering p53
levels in vitro
KRT81 3′ UTR miR-17 (hsa-miR-17-3p/5p) rs3660 (G > C) NHL Shorter survival time Chinese (210 cases vs.233 controls) Xie, 2014 [80]
C14orf101
(TMEM260) 3′ UTR Not specified rs4901706 (A > G) DLBCL
Shorter survival time/independent
predictor of overall survival
Chinese (96 cases vs.
90 controls) Yang, 2014 [81]
HIF1A 3′ UTR miR-196a (hsa-mir-196-5p) rs2057482 (C > T) Systemic HIV/AIDS NHL Increased risk
American HIV + men
(180 cases vs. 529 controls) Peckham, 2014 [73]
SET8 3′ UTR miR-502 (hsa-mir-502-5p) rs16917496 (C > T) NHL Shorter survival time (CC vs. CT only) Chinese (244 cases) Diao, 2014 [82]
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7. Conclusions
The ability of miRNAs to behave as molecular biomarkers for diagnosis, subtype classification,
drug resistance and prognosis in NHL is widely apparent. With advancing deep sequencing
technologies the identification of novel miRNA biomarkers is underway, however in order to properly
elucidate the roles of cellular, circulating and polymorphic miRNAs in lymphocyte biology and
pathophysiology of NHL, they need to be validated in other larger populations and functional studies
need to be performed in viable clinical samples, such as formalin-fixed paraffin-embedded (FFPE)
tumour tissue biopsies, which are suitable for reliable miRNA detection and measurement for more
than eight years from the time of processing [32]. Although results for circulating miRNAs are very
new, their ability to be used as non-invasive biomarkers for patients undergoing R-CHOP therapy for
ongoing detection of response to treatment and relapse is highly promising.
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